Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Progression of solitary and multifocal papillary thyroid carcinoma - a retrospective study of 368 patients.

Zheng XQ, Wang C, Xu M, Yu Y, Yun XW, Jia YS, Wei SF, Ren XB, Gao M.

Chin Med J (Engl). 2012 Dec;125(24):4434-9.

PMID:
23253715
[PubMed - indexed for MEDLINE]
Free Article
2.

BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.

Zheng X, Xia T, Lin L, Gao S, Lee Y, Yu Y, Wei S, Gao M.

World J Surg Oncol. 2012 Jun 8;10:104. doi: 10.1186/1477-7819-10-104.

PMID:
22681706
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10. Epub 2012 Mar 17.

PMID:
22426956
[PubMed - indexed for MEDLINE]
4.

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F.

J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.

PMID:
18682506
[PubMed - indexed for MEDLINE]
5.

Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.

Ahn HY, Chung YJ, Kim BS, Kang KH, Seok JW, Kim HS, Park SJ, Cho BY.

Surgery. 2014 Apr;155(4):689-95. doi: 10.1016/j.surg.2013.12.025. Epub 2013 Dec 27.

PMID:
24612623
[PubMed - indexed for MEDLINE]
6.

Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.

Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M.

Ann Surg Oncol. 2013 Jul;20(7):2266-73. doi: 10.1245/s10434-012-2851-z. Epub 2013 Jan 31.

PMID:
23370668
[PubMed - indexed for MEDLINE]
7.

BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.

Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ.

Thyroid. 2009 Apr;19(4):347-54. doi: 10.1089/thy.2008.0246.

PMID:
19355825
[PubMed - indexed for MEDLINE]
8.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
[PubMed - indexed for MEDLINE]
9.

Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.

Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.

Eur J Endocrinol. 2013 Apr 15;168(5):675-81. doi: 10.1530/EJE-12-1029. Print 2013 May.

PMID:
23416953
[PubMed - indexed for MEDLINE]
Free Article
10.

[Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].

Lin YK, Sheng JM, Zhao WH, Wang WB, Yu XF, Teng LS, Ma ZM.

Zhonghua Wai Ke Za Zhi. 2009 Mar 15;47(6):450-3. Chinese.

PMID:
19595234
[PubMed - indexed for MEDLINE]
11.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.

PMID:
23746767
[PubMed - indexed for MEDLINE]
12.

BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG.

Endocr Pathol. 2012 Jun;23(2):83-93. doi: 10.1007/s12022-011-9184-5.

PMID:
22105775
[PubMed - indexed for MEDLINE]
13.

The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.

Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M, Basolo F.

J Clin Endocrinol Metab. 2007 Sep;92(9):3511-6. Epub 2007 May 29.

PMID:
17535994
[PubMed - indexed for MEDLINE]
14.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.

PMID:
23571588
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.

Li C, Lee KC, Schneider EB, Zeiger MA.

J Clin Endocrinol Metab. 2012 Dec;97(12):4559-70. doi: 10.1210/jc.2012-2104. Epub 2012 Oct 9.

PMID:
23055546
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Paulson L, Shindo M, Schuff K, Corless C.

Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):44-9. doi: 10.1001/archoto.2011.226.

PMID:
22249628
[PubMed - indexed for MEDLINE]
17.

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.

Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.

JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1164-70. doi: 10.1001/jamaoto.2013.4501.

PMID:
24030686
[PubMed - indexed for MEDLINE]
18.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
[PubMed - indexed for MEDLINE]
19.

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.

Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x.

PMID:
22702340
[PubMed - indexed for MEDLINE]
20.

BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.

Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP.

Laryngoscope. 2014 Sep;124(9):E389-93. doi: 10.1002/lary.24668. Epub 2014 Apr 29.

PMID:
24604709
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk